-
Castration-Resistant Prostate Cancer CRPC or Hormone-Refractory Prostate Cancer HRPCA Therapeutics Market Report 2025
04 Jul 2025 16:49 GMT
… prostate cancer, increased usage of androgen deprivation therapy ADT leading to resistance, growing … include:
1 By Hormonal Therapy: Androgen Receptor AR Inhibitors, Androgen Synthesis Inhibitors, Luteinizing …
-
Regulatory recap: FDA approvals in urology from the first half of 2025
04 Jul 2025 15:41 GMT
… treated with an androgen receptor pathway inhibitor (ARPI) therapy and are … which found that darolutamide plus androgen deprivation therapy (ADT) significantly improved radiographic … makes darolutamide the first androgen receptor inhibitor indicated for …
-
Top 10 Urology Times videos from the first half of 2025
04 Jul 2025 15:41 GMT
… metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ … “Radical cystectomy versus bladder-sparing therapy for recurrent high-grade non … from the comparison of intravesical therapy and surgery as treatment options …
-
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
04 Jul 2025 06:01 GMT
… metastatic disease become resistant to androgen-deprivation therapy. Prostate cancer is the most …
-
Uncovering New Targets in Neuroendocrine Prostate Cancer
04 Jul 2025 03:58 GMT
… affecting men worldwide, with androgen deprivation therapy (ADT) serving as a … by low androgen receptor expression and heightened therapy resistance. This … mechanisms in cancer therapyMUC1 androgen receptor axisneuroendocrine prostate cancerphenotypic …
-
FDA Approval Insights: Darolutamide for Metastatic Castration-Sensitive Prostate Cancer: With Alicia Morgans, MD, MPH; and Neal Shore, MD, FACS
03 Jul 2025 20:29 GMT
… approval of darolutamide (Nubeqa) plus androgen deprivation therapy for patients with metastatic castration …
-
Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone
02 Jul 2025 20:34 GMT
… for fracture who are receiving androgen deprivation therapy for nonmetastatic prostate cancer, the … receiving an adjuvant aromatase inhibitor therapy for breast cancer, the prevention …
-
Suspending the NHS medicines repurposing programme in England is a missed opportunity
02 Jul 2025 17:16 GMT
… develop an alternative approach to androgen deprivation therapy in prostate cancer with fewer …
-
Oncology Drugs Approved by the FDA in June
02 Jul 2025 14:27 GMT
… either received standard gonadotropin-releasing androgen deprivation therapy (ADT) or had previously … following previous EGFR-targeted therapy and platinum-based chemotherapy. … in addition to standard androgen deprivation therapy and docetaxel in metastatic …
-
Prostate cancer management 2 – metastatic disease
02 Jul 2025 08:27 GMT
… metastases at presentation would include androgen deprivation therapy (ADT), which could be in … . Addition of docetaxel to hormonal therapy in low- and high-burden … V, et al. Imaging and therapy in prostate cancer using prostate …